Oskar Ström and Johan Liseth Hansen will be attending the ASCO 2026 Annual Meeting in Chicago from 29 May to 2 June.
They will be meeting partners and discussing the Quantify Research Nordic Oncology RWD Platform — a study-ready data asset built specifically for oncology real-world evidence generation.
Why this matters for oncology research:
🔹 Built around the patient journey
Pre-defined cohorts cover major solid tumours and haematological malignancies, enabling treatment sequencing, outcomes research, comparative effectiveness studies, and HEOR analyses.
🔹 Connected from diagnosis to outcomes
Cancer registry data are linked with hospital care, specialist visits, oncology medicines, biomarkers, laboratory results, procedures, sick leave, and cause of death within one analytical environment.
🔹 Designed for faster evidence generation
Variable definitions, validation logic, and quality control processes are already established, helping shorten timelines from research question to first results.
The Nordic oncology data environment remains uniquely valuable for RWE.
Mandatory reporting, population-wide coverage, and decades of longitudinal follow-up create opportunities that are difficult to replicate elsewhere. Personal identity numbers enable precise linkage across cancer, drug, patient, and mortality registers at national scale.
This makes long-term survival analyses, treatment pathway studies, rare cancer research, and subgroup analyses feasible beyond the limitations of single-centre datasets or claims databases.
If you are attending ASCO and would like to discuss oncology RWE, feel free to message Oskar or Johan to arrange a meeting.
